Home » Pipeline
Pipeline
October 14, 2019
| Company | Drug/Device | Medical Condition | Status |
|---|---|---|---|
| Yumanity Therapeutics | YTX-7739 | Parkinson’s disease | Phase 1 trial initiated enrolling 40 healthy subjects |
| Medivir AB | birinapant and radiation therapy | Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 1 trial initiated enrolling subjects with recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) |
| Debiopharm | Debio 1143, with Keytruda (pembrolizumab) | Pancreatic and colorectal cancer | Phase 1 trial initiated enrolling 46 subjects without other available therapeutic options |
| City of Hope | chimeric antigen receptor (CAR) T cells in combination with nivolumab (Opdivo) and ipilimumab (Yervoy) | glioblastoma | Phase 1 trial initiated |
| Hutchinson China MediTech Limited | HMPL-523 | relapsed or refractory lymphoma | Phase 1/1b trial initiated doising subjects with relapsed or refractory lymphoma at sites in the U.S. and Europe |
| Nektar Therapeutics | NKTR-358 (LY3471851) | psoriasis | Phase 1b trial initiated enrolling 40 subjects with plaque psoriasis |
| Nektar Therapeutics | NKTR-358 (LY3471851) | atopic dermatitis | Phase 1b trial initiated enrolling 40 subjects with atopic dermatitis |
| DURECT Corporation | DUR-928 | non-alcoholic steatohepatitis (NASH) | Phase 1b trial initiated enrolling 60 subjects with non-alcoholic steatohepatitis (NASH) with stage 1-3 fibrosis at multiple centers in the U.S. |
| AVROBIO, Inc. | investigational gene therapy | cystinosis | Phase 1/2 trial initiated four adult subjects and a potential follow-on cohort of two adults or adolescents at least 14 years of age who are currently being treated with cysteamine at UC San Diego |
| IDEAYA Biosciences, Inc. | cutaneous melanoma harboring a GNAQ or GNA11 (GNAQ/11) mutation | solid tumors | Phase 1/2 trial initiated |
| Minoryx Therapeutics | MIN-102 | Friedreich’s Ataxia | Phase 2 trial initiated enrolling 39 subjects ages 12-60 with Friedreich’s Ataxia in four European countries |
| Oncologie | bavituximab in combination with KEYTRUDA (pembrolizumab) | gastroesophageal cancer | Phase 2 trial initiated enrolling 80 subjects with advanced gastric or gastroesophageal cancer in the U.S., UK, South Korea and Taiwan |
| Frequency Therapeutics | FX-322 | Sensorineural Hearing Loss (SNHL) | Phase 2a trial initiated enrolling 96 adult subjects ages 18 to 65 with stable SNHL at 12 sites in the U.S. |
| DURECT Corporation | topical DUR-928 | mild to moderate plaque psoriasis | Phase 2a trial enrolling 20 subjects in the U.S. |
| Graybug Vision, Inc. | GB-102 | wet age-related macular degeneration (AMD) | Phase 2b trial initiated enrolling 160 subjects with wet AMD at more than 100 sites in the U.S. |
| iLiAD Biotechnologies, LLC | BPZE1 | pertussis | Phase 2b trial initiated enrolling 300 healthy subjects |
| Dermira, Inc. | lebrikizumab | moderate to severe atopic dermatitis | Phase 3 trial initiated enrolling 800 adult and adolescent patients ages 12 and older with moderate-to-severe atopic dermatitis at 200 sites in the U.S., Europe and Asia |
| Galderma | nemolizumab | moderate to severe atopic dermatitis | Phase 3 trial initiated |
| Seattle Genetics, Inc. | tucatinib in combination with ado-trastuzumab emtansine (T-DM1, Kadcyla) | breast cancer | Phase 3 trial initiated enrolling up to 460 subjects with unresectable locally-advanced or metastatic HER2+ breast cancer |
| Beckman Coulter, Inc. | DxA 5000 | pre-analytical sample quality detection | 510 (k) clearance granted by the FDA |
| Frequency Therapeutics | FX-322 | sensorineural hearing loss (SNHL) | Fast Track designation granted by the FDA |
| Novartis | Beovu (brolucizumab-dbll) | wet age-related macular degeneration (AMD) | Approval granted by the FDA |
| Clinuvel | Scenesse (afamelanotide) | erythropoietic protoporphyria (EPP) | Approval granted by the FDA |
| Gilead | Descovy | HIV pre-exposure prophylaxis | Approval granted by the FDA |
| AstraZeneca | FASENRA pen (benralizumab) | severe eosinophilic asthma | Approval granted by the FDA |
| Galderma | AKLIEF (trifarotene) Cream | acne | Approval granted by the FDA |
| Octapharma USA | WILATE | hemophilia A | Approval granted by the FDA |
Upcoming Events
-
26Jan
-
27Jan
-
11Feb
-
23Mar
-
26Apr
